^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation + RIPK1 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Zhongguo Shi Yan Xue Ye Xue Za Zhi
    Title:

    [Correlation of NK cell RIPK1 with Prognosis of Acute Myeloid Leukemia Patients with FLT3-ITD Mutation]

    Excerpt:
    The survival rate of AML patients with FLT3-ITD mutation in low RIPK1 activity after Rydapt treatment was significantly higher than that in high RIPK1 activity….The prognosis of AML patients with FLT3-ITD mutation closely relates with plasma RIPK1 activity and RIPK1 expression in NK cells.
    DOI:
    10.19746/j.cnki.issn.1009-2137.2020.05.009